Day One Biopharmaceuticals (DAWN) sold its Priority Review Voucher for $108M to an undisclosed buyer. The Company was awarded the PRV following the U.S. Food and Drug Administration accelerated approval of OJEMDA. As part of the transaction, $8.1M of the total consideration received from the sale of the PRV will be paid to Viracta Therapeutics (VIRX) to fully satisfy PRV related obligations of the Company’s license agreement with Viracta, dated December 16, 2019, as amended.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Announces Sale of Priority Review Voucher for $108 Million
- BrightSpring Health announces Onco360 selected as partner for OJEMDA
- Day One price target lowered to $40 from $50 at H.C. Wainwright
- Day One Biopharmaceuticals reports Q1 EPS (72c), consensus (66c)
- Day One Biopharmaceuticals Unveils Updated Corporate Presentation